Recombinant Human CD9-LEL Fc Chimera Protein, CF Summary
MD + (Pro100-Lys330)
Accession # P21926
Complete Your Research
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 500 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
When Recombinant Human CD9 Fc Chimera (Catalog # 10015-CD) is immobilized at 1 µg/mL, Biotinylated Recombinant CD81 Fc Chimera binds with an ED50 of 2-10 μg/mL.
2 μg/lane of Recombinant Human CD9 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 38-42 kDa and 75-85 kDa, respectively.
CD9, also known as Tspan29, is a 24-27 kDa cell surface protein belonging to the tetraspanin family (1). Common to other tetraspanins, CD9 is composed of four transmembrane domains, short N- and C-terminal cytoplasmic domains, and two extracellular loops. The larger extracellular loop, referred to as the LEL or EC2, contains highly conserved CCG and PXSC motifs (2, 3). The LEL mediates noncovalent protein-protein interactions, allowing tetraspanins to associate with each other as well as signaling molecules, structural proteins, and G-protein coupled receptors (4-6). Human CD9 is expressed in multiple cell and tissue types and has been identified in diverse biological roles due to its involvement in the formation of tetraspanin-enriched microdomains (TEMs). TEMs are associated with numerous processes ranging from cell adhesion and fusion, membrane trafficking, and endocytosis to leukocyte adherence and motility (4-7). These tetraspanin-enriched microdomains (TEMs) are associated with a wide range of functions from cell adhesion and fusion, membrane trafficking and endocytosis, and eukocyte adherence and motility. The LEL of human CD9 shares 77% and 84% amino acid sequence identity with mouse and rat CD9, respectively. CD9 can form homodimers or interact with other proteins including CD117, CD29, CD46, CD49c, CD81, CD315, Tspan4, TGF-alpha, and HBEGF (1, 4, 8-13). Increased expression of CD9 has been shown to enhance transmembrane TGF-alpha -induced EGFR stimulation (1), and injection of human CD9 mRNA into CD9 knock-out mouse oocytes restored sperm-egg fusion (14). CD9-LEL may also be involved in the inhibition of multinucleated giant cell formation (3) as well as possess anti-adhesive effects against bacteria trying to invade mammalian cells (6, 15). CD9 interacts with integrins to regulate cell adhesion and motility (16-18). CD9 has been implicated in platelet activation and aggregation (17, 19). It may act as the terminal signal of myelination in the peripheral nervous system and can regulate the formation of paranodal junctions (20). Also, it has been suggested CD9 plays an important role both in the self-antigen and recall antigen-induced T cell activation (21).
- Shi, W. et al. (2000) J. Cell Biol. 148:591.
- Hemler, M. (2003) Annu Rev Cell Biol. 19:397.
- Hulme, R. et al. (2014) PLoS One 9:e116289.
- Stipp, C. et al. (2003) Trends Biochem Sci. 28:106.
- Barreiro, O. et al. (2005) Blood 105:2852.
- Ventress, J. et al. (2016) PLoS One 11:e0160387.
- Rubinstein, E. (2011) Biochem Soc Trans. 39:501.
- Anzai, N. et al. (2002) Blood 99:4413.
- Radford, K. et al. (1996) Biochem. Biophys. Res. Commun. 222:13.
- Lozahic, S. et al. (2000) Eur. J. Immunol. 30:900.
- Park, K. et al. (2000) Mol. Hum. Reprod. 6:252.
- Charrin, S. et al. (2001) J. Biol. Chem. 276:14329.
- Tachibana, I. et al. (1997) J. Biol. Chem. 272:29181.
- Zhu, G. et al. (2002) Development 129:1995.
- Green, L. et al. (2011) Infect Immun. 79:2241.
- Powner, D. et al. (2011) Biochem. Soc. Trans. 39:563.
- Detchokul, S. et al. (2014) British Journal of Pharmacology 171:5462.
- Reyes, R. et al. (2018) Front. Immunol. 9:863.
- Slupsky, J. et al. (1989) J Biol chem. 264:12289.
- Ishibashi, T. et al. (2004) J. Neuroscience 24:96.
- Kobayashi, H. et al. (2004) Clin Exp Immunol. 137:101.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human CD9-LEL Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human CD9-LEL Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Human CD9-LEL Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image